 Infinity Pharmaceuticals Inc NASDAQ: INFI presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium SABCS. MARIO-3 Phase 2 trial is evaluating eganelisib in combination with Roche Holdings AGs OTC: RHHBY atezolizumab Tecentriq and Bristol-Myers Squibb Cos NYSE: BMY Abraxane nab-paclitaxel in frontline metastatic triple-negative breast cancer TNBC. 